An Evaluation of the Impact of REMS on Spontaneous Reporting for Marketed Products

被引：0

作者：

Jain, Reema ^{[1
]}

机构：

[1] Johns Hopkins Univ, Baltimore, MD USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2010年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

431

引用

页码：S183 / S183

页数：1

共 50 条

[1] New Guidance Documents for Reporting of Marketed Products
不详
PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 295 - 295
[2] New guidance documents for reporting of marketed products
Reactions Weekly, 2018, 1705 (1) : 2 - 2
[3] Impact of risk evaluation and mitigation strategy (REMS) programs
Reactions Weekly, 2021, 1853 (1) : 7 - 7
[4] Evaluation of cutaneous reactivity to recently marketed dermatologic products
Shelanski, MV
Phillips, SB
Potts, CE
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1996, 35 (02) : 137 - 140
[5] In Vitro Evaluation of Cytotoxic Activities of Marketed Herbal Products in Ghana
Languon, Sylvester
Tuffour, Isaac
Quayson, Emmanuel Ekow
Appiah-Opong, Regina
Quaye, Osbourne
JOURNAL OF EVIDENCE-BASED INTEGRATIVE MEDICINE, 2018, 23
[6] REMS Raise Concerns for Biotech Products
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2010, 23 (04) : 16 - 17
[7] EVALUATION OF A WORLDWIDE SPONTANEOUS REPORTING SYSTEM WITH CIMETIDINE
DAVIS, TG
PICKETT, DL
SCHLOSSER, JH
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 243 (19): : 1912 - 1914
[8] Can the FDA's Adverse Event Reporting System (FAERS) Data Be Used to Assess the Impact of interventions Such As Risk Evaluation and Mitigation Strategies (REMS)?
Wightman, Rachel S.
Stehr, Clayton
CLINICAL TOXICOLOGY, 2019, 57 (10) : 931 - 931
[9] The Impact of REMS on Pain Management
Hovestreydt, Lindsay R.
US PHARMACIST, 2011, 36 (05)
[10] THE IMPACT OF THE FDA'S RISK EVALUATION AND MITIGATION STRATEGIES (REMS) INITIATIVE ON PRESCRIPTION PATTERN FOR DRUGS APPROVED UNDER THE REMS PROGRAM AND RELEVANT NON-REMS COMPETITORS
Horowicz-Mehler, N.
Sepulveda, B.
White, C.
Doyle, J.
VALUE IN HEALTH, 2010, 13 (03) : A203 - A203

← 1 2 3 4 5 →